Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly (NYSE: LLY) reported results from a retrospective real‑world cohort study of 15,843 adults over 55 with overweight or obesity showing that sustained use of Zepbound (tirzepatide) for weight management was associated with lower non‑drug healthcare costs versus matched untreated controls.
Using pairwise and inverse probability of censoring weighting (IPCW) analyses that excluded Zepbound costs, estimated monthly healthcare costs were up to 15% lower (up to $181 per patient) at six months and up to $607 per patient per month at 12 months, corresponding to up to 38% lower costs. According to Lilly, cost savings from six months onward nearly offset, and from 12 months exceeded, the Medicare GLP‑1 Bridge program treatment cost of $195 per month, driven in part by lower hospital admissions and emergency department visits and higher routine outpatient visit rates. Results were published in Diabetes, Obesity and Metabolism.
Summary not available.
Lilly (NYSE: LLY) reported Q2 2026 revenue of $23.0 billion, up 48% year over year, driven mainly by surging volumes of Mounjaro and Zepbound. Reported EPS rose 26% to $7.94, while non-GAAP EPS increased 33% to $8.38, despite $3.03 per share of acquired IPR&D charges.
Gross margin reached 85.8% of revenue, and key products generated $15.7 billion, with strong growth in immunology, oncology, and neuroscience. Lilly raised 2026 revenue guidance to $85–$87 billion and increased non-GAAP performance margin guidance to 49.0%–50.5%, while updating non-GAAP EPS guidance to $35.50–$36.50.
Regulatory and pipeline progress included U.S. FDA approval of Ebglyss, European Commission approval of Jaypirca for CLL, positive Phase 3 data for retatrutide in obesity, and completion of a clinical package supporting global registrations starting with a planned U.S. BLA submission in Q1 2027. Business development featured completed acquisitions of Orna, Ajax, Centessa, and Kelonia, plus additional infectious disease deals and an agreement to acquire AtaiBeckley. Lilly also committed an extra $4.5 billion to expand Indiana manufacturing.
Eli Lilly (NYSE: LLY) announced that the U.S. FDA has granted Breakthrough Therapy designation to investigational KRAS G12C inhibitor olomorasib as monotherapy for adults with previously treated KRAS G12C‑mutant advanced pancreatic cancer, identified by an FDA‑approved test. This designation is based on preliminary data from the ongoing open‑label, multicenter Phase 1/2 LOXO‑RAS‑20001 trial in KRAS G12C‑mutant solid tumors, including pancreatic cancer after at least one prior systemic therapy.
According to Lilly, this is the second FDA Breakthrough Therapy designation for olomorasib, which previously received the status in combination with pembrolizumab (KEYTRUDA) for first‑line KRAS G12C‑mutant NSCLC with PD‑L1 ≥50%. Olomorasib is described as an oral, potent and highly selective next‑generation KRAS G12C inhibitor being studied across multiple global trials.
Eli Lilly (NYSE: LLY) reported positive topline Phase 3 results for its investigational triple agonist retatrutide in two 80‑week obesity trials, TRIUMPH‑2 and TRIUMPH‑3. In TRIUMPH‑2, adults with obesity or overweight and type 2 diabetes receiving 4 mg, 9 mg, and 12 mg weekly lost an average of 12.7%, 19.1%, and 20.8% of body weight (up to 49.6 lbs) and saw A1C reductions up to 1.6%, versus 4.0% weight loss and 0.2% A1C reduction on placebo.
In TRIUMPH‑3, adults with severe obesity and established cardiovascular disease lost 21.6% and 22.6% of body weight on 9 mg and 12 mg (up to 55.8 lbs) versus 3.2% on placebo, and showed reductions in triglycerides, non‑HDL cholesterol, systolic blood pressure, waist circumference, and hsCRP. MACE rates were numerically described with hazard ratios for MACE‑5 of 0.82 in‑study and 0.73 on‑treatment versus placebo. Gastrointestinal events were the most common adverse events, with higher discontinuation rates than placebo. Lilly plans to complete CMC work and submit a BLA for retatrutide to the U.S. FDA in Q1 2027; the molecule remains investigational and is not approved for sale.
Lilly (NYSE: LLY) plans to announce its second-quarter 2026 financial results on August 5, 2026, followed by a conference call with investors and media at 10 a.m. Eastern time. A live webcast and subsequent replay will be accessible via Lilly's investor relations website.
Eli Lilly (NYSE: LLY) signed a definitive agreement to acquire AtaiBeckley (Nasdaq: ATAI), a clinical-stage biopharma focused on rapid-acting neuroplastogens for mental health. AtaiBeckley’s lead asset, BPL-003, an intranasal synthetic 5-MeO-DMT for treatment-resistant depression, is in Phase 3 preparation and holds FDA Breakthrough Therapy Designation.
Lilly will pay $6.75 per share in cash at closing, plus up to $2.50 per share via a contingent value right tied to specified milestones for BPL-003 and VLS-01. The upfront consideration values AtaiBeckley’s equity at about $2.8 billion, with CVRs representing up to an additional $1.0 billion. The cash offer reflects a ~40% premium to AtaiBeckley’s 30-day VWAP through July 15, 2026. The deal is expected to close in the third quarter, subject to AtaiBeckley stockholder and regulatory approvals; it is not subject to a financing condition. About 15% of AtaiBeckley shares are already locked up through voting and support agreements.
Eli Lilly (NYSE: LLY) will present 16 Alzheimer's disease research abstracts at AAIC 2026 in London, July 12-15.
Highlights include new Kisunla (donanemab-azbt) long-term extension data on safety and biomarkers, and P-tau217 blood tests showing rule-in performance comparable to amyloid PET in cognitively unimpaired individuals.
Eli Lilly (NYSE: LLY) plans to present 16 Alzheimer's disease research abstracts at AAIC 2026 in London from July 12-15. The program includes new Kisunla (donanemab-azbt) long-term extension data, safety analyses, and biomarker findings, plus P-tau217 blood test performance compared with amyloid PET in cognitively unimpaired individuals.
Additional work covers imaging, health economics, real-world prescribing, and patient-centered outcomes, highlighting Lilly's 35-year focus on Alzheimer's science.
Innovent Biologics and Lilly (NYSE: LLY) signed a commercialization agreement for Verzenios (abemaciclib) in mainland China. Innovent gains sole commercialization rights, handling importation, marketing, distribution and promotion, while Lilly, as Marketing Authorization Holder, continues manufacturing, supply and development. Verzenios is NRDL-listed across early and advanced breast cancer indications.